24/7 Clients Support
- 24/7
Customer Service
- ISO 9001
Certification Company
- WHO-GMP
Certified Company
PALBOLIEVA 100MG is an Capsules medication used for treatment purposes. It is manufactured by Allieva Pharma Private Limited.
| Brand Name | PALBOLIEVA 100MG |
|---|---|
| Composition | Palbolieva Capsules 100mg |
| Manufacturer | Allieva Pharma Private Limited |
| Dosage Form | Capsules |
| Packaging | Btl (21 cap) |
| Country of Origin | India |
PALBOLIEVA 100MG (Palbolieva Capsules 100mg) is a widely used Capsules medicine manufactured by Allieva Pharma Private Limited. It is commonly prescribed for...
PALBOLIEVA 100 MG (Palbociclib Capsules 100 mg) is a prescription targeted anticancer medicine containing Palbociclib 100 mg, a highly effective CDK4/6 (Cyclin-Dependent Kinase 4 and 6) inhibitor used in the treatment of Hormone Receptor (HR)-Positive, HER2-Negative Breast Cancer. It is commonly prescribed in combination with hormone therapies to help slow cancer progression, control tumor growth, and improve patient outcomes.
Breast cancer remains one of the most frequently diagnosed cancers worldwide. Many breast cancer cells rely on hormones such as estrogen for growth and survival. In HR-positive breast cancer, abnormal activation of cellular pathways can cause uncontrolled cell division and tumor progression. PALBOLIEVA 100 MG is specifically designed to target these pathways by blocking CDK4 and CDK6 proteins, which are essential for cancer cell multiplication.
By preventing cancer cells from progressing through critical stages of the cell cycle, Palbociclib helps reduce tumor growth and delay disease progression. This targeted mechanism has significantly improved treatment strategies for patients with advanced and metastatic hormone receptor-positive breast cancer.
Unlike traditional chemotherapy, which affects rapidly dividing healthy and cancerous cells alike, Palbociclib offers a more precise approach by targeting specific proteins involved in cancer cell proliferation. This allows it to work effectively alongside endocrine therapies such as aromatase inhibitors and fulvestrant.
PALBOLIEVA 100 MG is commonly prescribed for:
The medicine is often used as part of personalized treatment strategies developed by oncologists based on the patient’s cancer stage, medical history, and treatment goals.
Manufactured under stringent pharmaceutical quality standards, PALBOLIEVA 100 MG is designed to provide consistent quality, safety, and therapeutic effectiveness.
Patients receiving Palbociclib therapy require regular monitoring, including complete blood counts, liver function assessments, infection evaluations, and routine clinical examinations to ensure safe and effective treatment.
Due to its proven efficacy and targeted mechanism of action, PALBOLIEVA 100 MG has become an important treatment option in modern breast cancer care worldwide.
PALBOLIEVA 100 MG (Palbociclib Capsules 100 mg) is primarily used for the treatment and management of hormone receptor-positive advanced breast cancer.
The medicine is widely prescribed for patients with hormone receptor-positive, HER2-negative breast cancer.
Palbociclib helps manage breast cancer that has spread to distant organs.
The medicine may be used in patients with advanced disease involving surrounding tissues.
Doctors may prescribe Palbociclib when breast cancer returns after previous treatment.
The medicine is commonly used alongside endocrine therapies to improve treatment outcomes.
Palbociclib helps delay cancer progression and maintain treatment response.
The medicine supports modern precision-based breast cancer treatment strategies.
Palbociclib belongs to a class of medicines known as CDK4/6 Inhibitors.
PALBOLIEVA works by:
This targeted mechanism helps improve disease control and support long-term treatment success.
Like all medicines, PALBOLIEVA 100 MG may cause side effects in some patients. The occurrence and severity of side effects vary among individuals.
One of the most frequently reported side effects that may increase infection risk.
Weakness and tiredness may occur during treatment.
Some patients may experience mild to moderate nausea.
Mild hair loss or hair thinning may occur.
Digestive disturbances may develop during treatment.
Inflammation or ulcers inside the mouth may occur.
Reduced appetite may affect nutritional intake.
The risk of infections may increase due to lowered white blood cell counts.
Some individuals may experience headaches during therapy.
Seek immediate medical attention if you experience:
Patients should contact their healthcare provider immediately if serious symptoms occur.
The dosage of PALBOLIEVA 100 MG (Palbociclib Capsules 100 mg) should always be determined by a qualified oncologist.
Treatment recommendations vary according to disease characteristics.
Regular blood monitoring helps guide dosage adjustments.
Doctors may modify therapy according to effectiveness and tolerability.
Liver and kidney health may influence treatment planning.
Certain medicines may require dosage modifications due to interactions.
Before starting treatment, inform your doctor if you have:
Patients should also disclose all prescription medicines, supplements, and herbal products they are currently taking to avoid potential drug interactions.
Pregnant or breastfeeding women should only use this medicine if specifically recommended by a healthcare professional.
It is primarily used for the treatment of HR-positive, HER2-negative advanced or metastatic breast cancer.
Palbociclib is a targeted anticancer medicine that blocks CDK4 and CDK6 proteins involved in cancer cell division.
No. It is a targeted therapy known as a CDK4/6 inhibitor and works differently from traditional chemotherapy.
It is usually prescribed in combination with hormone therapies such as aromatase inhibitors or fulvestrant.
Palbociclib can lower white blood cell counts, making regular monitoring essential.
Yes. Reduced white blood cell counts may increase susceptibility to infections.
Treatment duration depends on disease response, patient tolerance, and the oncologist’s recommendations.
Yes. This medicine should only be used under the supervision of qualified healthcare professionals experienced in oncology and breast cancer treatment.